Steven P. Treon, M.D., Ph.D.
Co-Author
This page shows the publications co-authored by Steven Treon and Andrew Branagan.
Connection Strength
4.224
-
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024.
Score: 0.246
-
Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
Score: 0.243
-
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021 10 28; 138(17):1535-1539.
Score: 0.242
-
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
Score: 0.240
-
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733.
Score: 0.231
-
Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
Score: 0.230
-
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
Score: 0.224
-
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
Score: 0.215
-
Genomic landscape of Waldenström's macroglobulinemia. Hemasphere. 2019 Jun; 3(Suppl).
Score: 0.206
-
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
Score: 0.099
-
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16; 113(16):3673-8.
Score: 0.099
-
Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
Score: 0.097
-
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9.
Score: 0.093
-
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
Score: 0.091
-
Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
Score: 0.090
-
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 01; 13(11):3320-5.
Score: 0.089
-
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
Score: 0.086
-
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan; 7(4):286-90.
Score: 0.086
-
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol. 2006 Nov; 124(11):1601-6.
Score: 0.085
-
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82.
Score: 0.083
-
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83.
Score: 0.083
-
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006 May 01; 107(9):3442-6.
Score: 0.081
-
Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006 Mar; 17(3):488-94.
Score: 0.080
-
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):246-9.
Score: 0.076
-
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81.
Score: 0.076
-
Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan; 16(1):132-8.
Score: 0.075
-
Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004 Dec; 5(3):205-7.
Score: 0.075
-
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004 Oct; 15(10):1481-3.
Score: 0.074
-
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
Score: 0.067
-
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 Mar 07.
Score: 0.062
-
Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 Feb 24.
Score: 0.062
-
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624.
Score: 0.059
-
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021 Jun 24.
Score: 0.059
-
Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
Score: 0.058
-
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
Score: 0.056
-
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433.
Score: 0.055
-
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31.
Score: 0.017
-
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5.
Score: 0.017
-
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):116-20.
Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.